This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Oak Street Health Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Oak Street Health kazanç ve gelirin sırasıyla yıllık 53.6% ve 23.4% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 55.2% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 31.9% olacağı tahmin edilmektedir.

Anahtar bilgiler

53.6%

Kazanç büyüme oranı

55.2%

EPS büyüme oranı

Healthcare kazanç büyümesi	19.0%
Gelir büyüme oranı	23.4%
Gelecekteki özkaynak getirisi	31.9%
Analist kapsamı	Good
Son güncelleme	02 May 2023

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

NYSE:OSH - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2025	5,215	-120	-88	117	5
12/31/2024	4,117	-263	-191	-84	14
12/31/2023	3,053	-363	-289	-227	17
12/31/2022	2,161	-509	-399	-309	N/A
9/30/2022	1,977	-515	-393	-285	N/A
6/30/2022	1,820	-494	-398	-295	N/A
3/31/2022	1,650	-442	-353	-260	N/A
12/31/2021	1,430	-409	-278	-197	N/A
9/30/2021	1,285	-358	-230	-181	N/A
6/30/2021	1,114	-282	-147	-116	N/A
3/31/2021	976	-159	-94	-69	N/A
12/31/2020	883	-120	-98	-77	N/A
9/30/2020	808	-85	-77	-57	N/A
6/30/2020	729	-93	-103	-79	N/A
3/31/2020	641	-145	-88	-63	N/A
12/31/2019	557	-137	-83	-55	N/A
9/30/2019	470	-119	-65	-35	N/A
12/31/2018	318	-119	-101	-75	N/A
12/31/2017	185	-55	-48	-35	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: OSH önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: OSH önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: OSH önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: OSH şirketinin gelirinin (yıllık 23.4% ) US pazarından (yıllık 9.1% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: OSH şirketinin gelirinin (yıllık 23.4% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: OSH 'in Özsermaye Getirisi'nin 3 yıl içinde yüksek olması tahmin ediliyor ( 31.9 %)

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2023/05/03 06:57
Gün Sonu Hisse Fiyatı	2023/05/01 00:00
Kazançlar	2022/12/31
Yıllık Kazançlar	2022/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Oak Street Health, Inc. 22 Bu analistlerden 17, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Matthew Gillmor	Baird
Sarah James	Barclays
Kevin Fischbeck	BofA Global Research

This company has been acquired

Oak Street Health Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target increased by 8.5% to US$35.00

Oak Street Health, Inc. Provides Earnings Guidance for the Year Ending December 31, 2022

Consensus forecasts updated

Price target increased to US$31.78

Oak Street Health, Inc. Provides Earnings Guidance for the Three Months Ending September 30, 2022 and Twelve Months Ending December 31, 2022

Oak Street Health, Inc. Provides Earnings Guidance for the Second Quarter Ending June 30, 2022 and for the Full Year Ending December 31, 2022

Recent updates

Chief Innovation Officer & Director notifies of intention to sell stock

Chief Financial Officer recently sold US$232k worth of stock

Chief Innovation Officer & Director notifies of intention to sell stock

Chief Innovation Officer & Director notifies of intention to sell stock

Chief Innovation Officer & Director notifies of intention to sell stock

Chief Innovation Officer & Director recently sold US$274k worth of stock

Full year 2022 earnings: EPS misses analyst expectations

Chief Innovation Officer & Director notifies of intention to sell stock

Chief Innovation Officer & Director notifies of intention to sell stock

CVS Health Corporation (NYSE:CVS) entered into a definitive agreement to acquire Oak Street Health, Inc. (NYSE:OSH) from Newlight Partners LP, General Atlantic LLC and others for $9.6 billion.

Price target increased by 8.5% to US$35.00

CVS Health Corporation (NYSE:CVS) entered into a definitive agreement to acquire Oak Street Health, Inc. (NYSE:OSH) from Newlight Partners LP, General Atlantic LLC and others for $9.6 billion.

CVS close to acquiring Oak Street Health for $10.5B - WSJ

Chief Legal Officer & Secretary notifies of intention to sell stock

Chief Innovation Officer & Director notifies of intention to sell stock

CVS Reportedly Explores an Acquisition of Oak Street Health

Oak Street Health jumps on report of CVS takeover interest

Chief Operating Officer notifies of intention to sell stock

Oak Street Health, Inc. Appoints Deb Edberg as First Chief Wellness Officer

Chief Innovation Officer & Director notifies of intention to sell stock

Chief Operating Officer notifies of intention to sell stock

Oak Street Health, Inc. announced that it has received funding

Oak Street Health pares gain on report about takeover chances

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Oak Street Health, Inc. Provides Earnings Guidance for the Year Ending December 31, 2022

Oak Street Health Q3 2022 Earnings Preview

Chief Operating Officer notifies of intention to sell stock

Oak Street Health, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Chief Operating Officer notifies of intention to sell stock

Board Member notifies of intention to sell stock

Oak Street Health Launches Nurse Practitioner Fellowship in Adult Primary Care

Oak Street Health downgraded at Goldman Sachs citing cloudy outlook

Chief Innovation Officer & Director notifies of intention to sell stock

Chief Innovation Officer & Director notifies of intention to sell stock

Chief Operating Officer recently sold US$258k worth of stock

Oak Street Health, Inc. has completed a Follow-on Equity Offering in the amount of $180.25 million.

Oak Street Health, Inc. has completed a Follow-on Equity Offering in the amount of $180.25 million.

Oak Street Health slips aftermarket on secondary stock offering

Consensus forecasts updated

CEO & Chairman notifies of intention to sell stock

Price target increased to US$31.78

Second quarter 2022 earnings: EPS misses analyst expectations

Oak Street Health, Inc. Provides Earnings Guidance for the Three Months Ending September 30, 2022 and Twelve Months Ending December 31, 2022

Oak Street Health Q2 2022 Earnings Preview

Chief Innovation Officer & Director notifies of intention to sell stock

Chief Innovation Officer & Director notifies of intention to sell stock

Oak Street Health, Inc. to Report Q2, 2022 Results on Aug 02, 2022

Chief Innovation Officer & Director notifies of intention to sell stock

Chief Innovation Officer & Director notifies of intention to sell stock

Chief Innovation Officer & Director notifies of intention to sell stock

Oak Street Health, Inc. Provides Earnings Guidance for the Second Quarter Ending June 30, 2022 and for the Full Year Ending December 31, 2022

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Chief Innovation Officer & Director notifies of intention to sell stock

Chief Innovation Officer & Director notifies of intention to sell stock

Oak Street Health, Inc. to Report Q1, 2022 Results on May 03, 2022

Chief Innovation Officer & Director notifies of intention to sell stock

Full year 2021 earnings: EPS exceeds analyst expectations

Jakubowitz Law Commences Securities Fraud Class Action Lawsuit on Behalf of Shareholders of Oak Street Health, Inc

Oak Street Health, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Price target decreased to US$46.00

Chief Innovation Officer & Director notifies of intention to sell stock

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Oak Street Health, Inc

Price target decreased to US$50.38

President notifies of intention to sell stock

Chief Innovation Officer & Director notifies of intention to sell stock

Oak Street Health Grows Revenue But Struggles With Higher Medical Costs

COO & Director exercised options to buy US$161k worth of stock.

Chief Legal Officer & Secretary exercised options and sold US$210k worth of stock